Actively Recruiting

All Genders
ID06421805

A Single-center, Prospective, and Observational Study on Population Characteristics, Pathological Features, and Prognostic Factors of Patients With Mediastinal Tumor: Establishing Mediastinal Tumor Database of PUMCH

Led by Peking Union Medical College Hospital · Updated on 2024-05-20

2000

Participants Needed

1

Research Sites

52 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This research aims to collect and analyze information on patients with mediastinal tumors, including their population characteristics, imaging and pathological features, and factors that affect prognosis. Mediastinal tumors are a diverse group of rare tumors located in the mediastinum, which can be benign or malignant and may invade nearby structures or arise from metastases. The study seeks to build a specialized database at Peking Union Medical College Hospital to enhance diagnosis, treatment quality, and clinical decision-making for these tumors. The study is observational and does not involve experimental treatments. It categorizes mediastinal tumors into groups such as thymoma, teratomas, germ cell tumors, lymphomas, neuroendocrine tumors, neurinomas, thymic carcinoma, and others. Researchers will document clinical data and tumor characteristics over time, aiming to integrate resources and improve patient management by establishing a comprehensive, standardized mediastinal tumor database. Participants will provide clinical and pathological information, which will be structured and analyzed. Researchers will monitor outcomes including overall survival and progression-free survival for up to 20 years from enrollment. This long-term observation will provide valuable data to support future clinical protocols and improve understanding of mediastinal tumors. The study will continue until 2045, allowing extensive follow-up.

CONDITIONS

Brief Title

Establishing Prospective Mediastinal Tumor Database of PUMCH

Who Can Participate

All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Clinical or pathological diagnosis of mediastinal tumors
  • Ability to provide written consent
Not Eligible

You will not qualify if you...

  • Incomplete clinicopathological information

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Long-term Monitoring

Duration - Up to 20 years

Participants diagnosed with mediastinal tumors are observed over time to collect data on overall survival and progression-free survival.

Periodic visits for assessments over 20 years

Trial Site Locations

Total: 1 location

1

Peking Union Medical College Hospital

Beijing, Beijing Municipality, China, 100730

Actively Recruiting

Loading map...

Research Team

X

Xuehan Gao, MD

Y

Yeye Chen, MD

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

8

Similar Trials

Use of [F-18] FLT for Imaging With Positron Emission Tomogra...

Brain and Central Nervous System Tumors

Actively Recruiting

1 location

Pilot Trial of Telehealth Music Therapy for Cognitive Dysfun...

Blood Cancer

Actively Recruiting

7 locations

A Phase 1 Open-label Study to Evaluate the Safety, Tolerabil...

Advanced Solid Tumor

Actively Recruiting

4 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here